deltatrials
Completed INTERVENTIONAL NCT03213678

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Malignant Solid Neoplasm Ann Arbor Stage III Non-Hodgkin Lymphoma Ann Arbor Stage IV Non-Hodgkin Lymphoma Malignant Glioma Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Primary Central Nervous System Neoplasm Recurrent Rhabdomyosarcoma Recurrent Soft Tissue Sarcoma Refractory Langerhans Cell Histiocytosis Refractory Malignant Germ Cell Tumor Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Primary Central Nervous System Neoplasm Rhabdoid Tumor Stage III Osteosarcoma AJCC v7 Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Osteosarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Stage IVA Osteosarcoma AJCC v7 Stage IVB Osteosarcoma AJCC v7 Wilms Tumor
Interventions Biospecimen Collection Computed Tomography FDG-Positron Emission Tomography Magnetic Resonance Imaging Samotolisib X-Ray Imaging
Updated 81 times since 2017 Last updated: Apr 1, 2026 Started: Nov 28, 2017 Primary completion: Sep 30, 2023 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Advanced Malignant Solid Neoplasm and Ann Arbor Stage III Non-Hodgkin Lymphoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 81 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with samotolisib (LY3023414) with advanced solid tumors, non-Hodgkin lymphomas or central nervous system (CNS) tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations. SECONDARY OBJECTIVES: I. To estimate the progression free survival in pediatric patients treated with LY3023414 with advanced solid tumors, non-Hodgkin lymphomas or CNS tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations. II. To obtain information about the tolerability of LY3023414 in children with relapsed or refractory cancer. III. To characterize the pharmacokinetics of LY3023414 in children with recurrent or refractory cancer. EXPLORATORY OBJECTIVES: I. To increase knowledge of the genomic landscape of relapsed pediatric solid tumors and lymphomas and identify potential predictive biomarkers (other than the genomic alteration for which study treatment was assigned) using additional genomic, transcriptomic, and proteomic testing platforms. II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA). III. To evaluate the frequency and mechanism of biallelic loss of function, and evaluate the expression of TSC1, TSC2, and PTEN in subjects who enroll with a...

PRIMARY OBJECTIVE:

I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with samotolisib (LY3023414) with advanced solid tumors, non-Hodgkin lymphomas or central nervous system (CNS) tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations.

SECONDARY OBJECTIVES:

I. To estimate the progression free survival in pediatric patients treated with LY3023414 with advanced solid tumors, non-Hodgkin lymphomas or CNS tumors that harbor TSC loss of function mutations, and/or other PI3K/MTOR activating mutations.

II. To obtain information about the tolerability of LY3023414 in children with relapsed or refractory cancer.

III. To characterize the pharmacokinetics of LY3023414 in children with recurrent or refractory cancer.

EXPLORATORY OBJECTIVES:

I. To increase knowledge of the genomic landscape of relapsed pediatric solid tumors and lymphomas and identify potential predictive biomarkers (other than the genomic alteration for which study treatment was assigned) using additional genomic, transcriptomic, and proteomic testing platforms.

II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).

III. To evaluate the frequency and mechanism of biallelic loss of function, and evaluate the expression of TSC1, TSC2, and PTEN in subjects who enroll with a loss of function mutation in one of these genes.

OUTLINE: This is a dose-escalation study.

Patients receive samotolisib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, computed tomography (CT), magnetic resonance imaging (MRI), fludeoxyglucose F-18 (FDG)-position emission tomography (FDG-PET), and blood sample collection on study.

After completion of study treatment, patients are followed up periodically.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Apr 2026 · 8 months · monthly snapshotApr 21, 2026 – present · 3 months · daily API

Change History

81 versions recorded

  1. Apr 21, 2026 — Present [daily]

    Completed

    Phase: PHASE2 → None

  2. Sep 2025 — Apr 2026 [monthly]

    Completed PHASE2

  3. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 76 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  4. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  8. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  9. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  10. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  11. Jun 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  13. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  14. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  15. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  16. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  17. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  18. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  19. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  20. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  21. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  22. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  23. May 2022 — Jun 2022 [monthly]

    Suspended PHASE2

  24. Apr 2022 — May 2022 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  25. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  26. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  27. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  28. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  29. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  30. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  31. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  32. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  33. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  34. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  35. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  36. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  37. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  38. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  39. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  40. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  41. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  42. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  43. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  44. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  45. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  46. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  47. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  48. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  49. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  50. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  51. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  52. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  53. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  54. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  55. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  56. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  57. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  58. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  59. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

  60. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  61. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  62. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  63. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  64. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  65. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  66. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  67. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  68. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  69. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  70. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  71. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  72. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  73. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  74. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  75. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  76. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). Samotolisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Anchorage, United States , Ann Arbor, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Austin, United States , Baltimore, United States , Baltimore, United States , Bangor, United States and 117 more locations